Share. Connect. Create. Grow. · Socialiya
Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts

Oruka Therapeutics' long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in...

BUSINESS NEWS April 27, 2026

Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts

Oruka Therapeutics' long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading Jefferies analysts to predict...

15 views 0 likes 0 comments
Share:
Oruka Therapeutics' long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading Jefferies analysts to predict...

Author: Fierce Biotech

Read Original Article

Related News

Latest News

Advertisement

Top Categories

Advertisement
Advertisement
Advertisement
Advertisement